Document is current
Any future updates will be listed below
-
Authors
Berrino, Enrico
Annaratone, Laura
Bellomo, Sara Erika
Ferrero, Giulio
Gagliardi, Amedeo
Bragoni, Alberto
Grassini, Dora
Guarrera, Simonetta
Parlato, Caterina
Casorzo, Laura
Panero, Mara
Sarotto, Ivana
Giordano, Silvia
Cereda, Matteo
Montemurro, Filippo
Ponzone, Riccardo
Crosetto, Nicola
Naccarati, Alessio
Sapino, Anna
Marchiò, Caterina https://orcid.org/0000-0003-2024-6131
-
Funding
Funding for this research was provided by:
Associazione Italiana per la Ricerca sul Cancro (IG2019 22850, MFAG 2017 - ID 20566)
Ministero dell’Istruzione, dell’Università e della Ricerca (D15D18000410001)
Ministero della Salute (FPRC 5X1000 MS2017 PTCRC)
- License Information
-
More Information
Article History
Received: 14 March 2022
Accepted: 10 August 2022
First Online: 29 August 2022
Declarations
:
: A written informed consent of the “Profiling” protocol (“Profiling” #001-IRCC-00IIs-10) was signed by all of the patients whose tumor was analyzed in this study. “Profiling” is an observational, non-interventional protocol for sample collection enabling an experimental platform for molecular studies and/or creation of preclinical models with patients’ informed consent, approved by the “Istituto di Candiolo FPO-IRCCS” Ethical Committee. The protocol holds a registration number in , Identifier: NCT03347318.The research described in this study conformed to the principles of the Helsinki Declaration.
: Not applicable.
: CM reports personal consultancy fees from Bayer, Roche, AstraZeneca, and Daiichi Sankyo. FM reports personal fees for consultancy or speaker’s engagements from Roche, Novartis, Pfizer, Astra Zeneca, MSD, Eli Lilly, Daiichi Sankyo, and SeaGen. The remaining authors declare that they have no competing interests.
